Drug Trial Radar · NCT01951209
Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis
Last checked: Nov 20, 2026Latest source record: Mar 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Nov 17, 2016
Primary completion
Nov 17, 2016
Study completion Jun 12, 2017
Sponsor
- Lead sponsor
- David E. Kaplan, MD MScFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Bausch Health Americas, Inc.
- First posted
- Sep 26, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hepatitis C is the leading cause of chronic liver disease and cirrhosis in United States veterans. Cirrhosis is associated with impaired antibody responses and increased risk of bacterial infections. We have recently identified that cirrhosis is associated with abnormalities of memory B-cells, cells that make antibodies and help protect against bacterial infections. We have identified that chemicals associated with gut bacteria might play a role in causing these B-cell abnormalities. It is well known that gut bacteria have increased access to the blood in individuals with cirrhosis, a process called bacterial translocation. We hypothesize that reducing bacteria counts in the gut by using poorly-absorbed antibiotics (also known as selective gut decontamination) will partially reverse losses of memory B-cells in cirrhosis by reducing bacterial translocation.
Conditions
- Liver Cirrhosis
- Chronic Hepatitis C
Interventions
RifaximinDrug
550mg orally twice daily for 12 weeks
PlaceboDrug
Matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in CD27+ B-cell frequencyTime frame: Week 0 (Baseline) to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Philadelphia VA Medical Center
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.